# FDA Approves Eli Lilly's Foundayo, First Restriction-Free GLP-1 Weight Loss Pill

*2026-04-02 12:02 UTC · Science · 1 min read*

> FDA fast-tracks Eli Lilly's Foundayo, the first GLP-1 weight loss pill with no food or timing restrictions, priced from $149/month.

The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1 in a fast-tracked 50-day review — the fastest for a new drug class since 2002. The daily pill is the first oral GLP-1 medication that can be taken any time of day without food or water restrictions, unlike Novo Nordisk's rival Wegovy pill which requires a 30-minute fast before meals.

In clinical trials, patients on the highest dose lost an average of 11.2% body weight over 72 weeks. While less potent than injectable options like Zepbound (21%) or Wegovy shots (15%), the convenience of a simple pill with no restrictions could drive mass adoption. Cash prices range from $149 to $349 per month, with insured patients potentially paying as low as $25 per month using a Lilly discount card.

Prescriptions are being accepted immediately via LillyDirect, with shipping starting April 6. The drug requires no cold-chain storage, simplifying distribution compared to injectables. Foundayo enters a rapidly growing market — Novo Nordisk's Wegovy pill has already garnered over 600,000 prescriptions since its December approval.

## Sources

- [pbs.org](https://www.pbs.org/newshour/health/fda-grants-speedy-approval-to-eli-lillys-weight-loss-pill-for-obesity)
- [statnews.com](https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/)

---
TechTools News · https://techtools.cz/tools/news/article/1221-fda-approves-eli-lilly-s-foundayo-first-restriction-free-glp-1-weight-loss-pill
Česká verze: https://techtools.cz/tools/news/clanek/1271-fda-schvalila-foundayo-od-eli-lilly-prvni-pilulku-na-hubnuti-glp-1-bez-omezeni
